Veracyte Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Veracyte Inc 's ROA in the second quarter of 2026?
Veracyte Inc achieved a return on average assets (ROA) of 8.04 % in its second quarter of 2026 a new company high.

Despite the company's net income deteriorating, Veracyte Inc was able to improve its ROA compared to the first quarter of 2026.

However, within the Healthcare sector 116 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 985, from total ROA ranking in the first quarter of 2026 at 1396.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	10.58 %	9.14 %	8.02 %	7.24 %	8.98 %
Y / Y Net Income Change	-	307.36 %	704.79 %	26.28 %	-
Net Income (TTM) in million	114	88	66	30	26
Return On Assets (TTM)	8.04 %	6.34 %	4.88 %	2.27 %	2.01 %
VCYT's Total Ranking	# 985	# 1396	# 1774	# 1828	# 1694
Total Assets (TTM) in million	1,488	1,436	1,406	1,368	1,346
Seq. Total Assets Change	3.6 %	2.16 %	2.74 %	1.69 %	2.25 %
Seq. Net Income Change	-11.21 %	-30.24 %	115.02 %	-	-

VCYT's 5 Years Annual ROA >> Back to VCYT Management Effectiveness >> Compare VCYT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 4
Sector	# 117
Overall	# 763

Return On Assets Statistics
High	Average	Low
8.04 %	-18.62 %	-52.09 %
(Jun 30 2026)		(Mar 31 2014)

Financial Statements
Veracyte Inc 's Assets	$ 1,488 million	VCYT's Balance sheet
Veracyte Inc 's Income	$ 25 million	Quarterly VCYT's Income Statement
VCYT's Income by Division		See VCYT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	8.02 %	16.65 %	-3.58 %	-2.58 %	159.83 %
Total Assets in million	1,406	1,302	1,116	1,157	1,188
Y / Y Net Income Change	174.89 %	-	-	-	-
Net Income in million	66	24	-74	-37	-76
Annual Return On Assets	4.72 %	1.85 %	-6.67 %	-3.16 %	-6.36 %

VCYT's 5 Years Annual ROA >> Back to VCYT Management Effectiveness >> Compare VCYT ROA to its Competitors

Comment on VCYT's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 4.72 % compared to prior year, due to annual net income growth of 174.89 % to $66.35 million, while value of Veracyte Inc 's overall assets grew just by 8.02 % to $1,406.02 million, compared to $1,406.02 a year before.

More Return On Assets Ratios
VCYT's' Return on Assets at Yahoo Finance
Medical Laboratories Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VCYT's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VCYT's Competitors
Subscribers only: Roa for Veracyte Inc 's Suppliers
Subscribers only: Return On Assets for VCYT's Customers

You may also want to know
VCYT's Roi	VCYT's Inventory Turnover Ratio	VCYT's Growth Rates	VCYT's Dividend Comparisons
	VCYT's Profitability Ratios	VCYT's Asset Turnover Ratio	VCYT's Dividend Growth
VCYT's Roe	VCYT's Valuation Ratios	VCYT's Financial Strength Ratios	VCYT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %
Aveanna Healthcare Holdings Inc	13.82 %
West Pharmaceutical Services Inc	13.64 %
Medinotec Inc	13.38 %
Puma Biotechnology Inc	13.28 %

Date modified: 2026-09-02T19:45:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.